Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.02%
#3 CoW Protocol CoW Protocol +39.55%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +25.07%
#6 Walrus Walrus +22.69%
#7 Enso Enso +21.93%
#8 Tutorial Tutorial +17.35%
#9 Codatta Codatta +16.76%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Amniotics AB (publ) Amniotics AB (publ)

Amniotics AB (publ)

AMNI
Kedudukan dalam Saham #37511
Amniotics AB (publ) specializes in the creation, manufacturing, and... Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Harga Saham
$0.00060315
Disegerakkan terakhir: 2024-09-27
Modal Pasaran
$1.65M
Perubahan (1 hari)
19.64%
Perubahan (1 tahun)
0.00%
Negara
SE
Perdagangan Amniotics AB (publ) (AMNI)

Kategori

Healthcare
Pendapatan untuk Amniotics AB (publ) (AMNI)
Pendapatan pada Dec 2023 TTM: $-3.09M
Menurut laporan kewangan terkini Amniotics AB (publ), pendapatan semasa syarikat ialah $-3.09M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-4.61M, peningkatan berbanding pendapatan pada tahun 2021 yang berjumlah $-5.92M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Amniotics AB (publ) dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-3.09M 0.85%
2023 $-3.06M -33.59%
2022 $-4.61M -22.23%
2021 $-5.92M 57.96%
2020 $-3.75M 235.76%
2019 $-1.12M 45.50%
2018 $-767.77K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -171,033.57%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -63,310.98%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -97,500.51%
BE